Uttarakhand Suspends Permissions Of 14 Products Of Ramdev’s Pharma Firms

Haridwar: An Indian state regulator has suspended manufacturing licences of 14 products made by pharmaceutical companies of the country’s most popular yoga guru for repeatedly publishing misleading advertisements about their efficacy, a government order showed.

The order is the latest setback for Baba Ramdev whose TV shows, yoga cures and traditional medicine offerings for diseases have made him popular in India and other nations.

The Supreme Court of India has in recent weeks repeatedly criticised Ramdev for not complying with its directives in an ongoing lawsuit to stop misleading advertisements of some of his traditional ayurvedic medicines.

The manufacturing permits of Ramdev’s companies were suspended in an April 15 order by the drug regulator of traditional medicines in northern Uttarakhand state. Reuters is the first to report the order which is not public.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

Related Posts

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

The Maharashtra Food and Drug Administration (FDA) seized 3,098.46 tonnes of food stock worth Rs 63.45 crore and suspended 954 food licences during a statewide enforcement drive in the past…

Stents to syringes: Serious harm reports surge, but makers remain unnamed

6-year data disclosed first time by Indian Pharmacopoeia Commission on CIC order The Indian Pharmacopoeia Commission (IPC) has, for the first time, disclosed the number of Serious Adverse Events (SAEs)…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

Stents to syringes: Serious harm reports surge, but makers remain unnamed

Stents to syringes: Serious harm reports surge, but makers remain unnamed

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Medicines that cure Us are making Our Environment Sick

Medicines that cure Us are making Our Environment Sick